NASDAQ:NRXP NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free NRXP Stock Alerts $2.82 0.00 (0.00%) (As of 10:32 AM ET) Add Compare Share Share Today's Range$2.74▼$2.8750-Day Range$2.06▼$70.0652-Week Range$1.90▼$12.00Volume64,682 shsAverage Volume308,869 shsMarket Capitalization$29.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get NRx Pharmaceuticals alerts: Email Address Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About NRx Pharmaceuticals Stock (NASDAQ:NRXP)NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.Read More NRXP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRXP Stock News HeadlinesMay 8, 2024 | markets.businessinsider.comNRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone UpdateMay 8, 2024 | prnewswire.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024May 9, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.May 7, 2024 | prnewswire.comNRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024May 6, 2024 | marketwatch.comNRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial DataMay 6, 2024 | markets.businessinsider.comNRx Pharmaceuticals Plans To Seek Accelerated Approval Of NRX-101 - Quick FactsMay 6, 2024 | prnewswire.comNRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar DepressionMay 1, 2024 | americanbankingnews.comShort Interest in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Expands By 20.3%May 9, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.April 30, 2024 | prnewswire.comNRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar DepressionApril 18, 2024 | investorplace.comWhy Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today?April 18, 2024 | finance.yahoo.comNRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common StockApril 18, 2024 | finance.yahoo.comNRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price RequirementApril 18, 2024 | prnewswire.comNRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price RequirementApril 18, 2024 | prnewswire.comNRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common StockApril 17, 2024 | markets.businessinsider.comNRx Pharmaceuticals: New Data Demonstrates No Impact Of NRX-101 On Gut Or Vaginal FloraApril 17, 2024 | finance.yahoo.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infectionsApril 15, 2024 | prnewswire.comNRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)April 14, 2024 | msn.comNRx Pharmaceuticals Advances in Breakthrough Bipolar Depression TreatmentApril 8, 2024 | markets.businessinsider.comNRx Pharma Achieves Data-lock In Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression StudyApril 8, 2024 | prnewswire.comNRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar DepressionApril 3, 2024 | msn.comNew Brain Cap Lets People Play Video Games With Their MindsApril 3, 2024 | ca.news.yahoo.comWoman, 23, diagnosed with cancer after thinking she was bloated with irritable bowel syndromeApril 3, 2024 | ca.news.yahoo.comRep. Raúl Grijalva announces cancer diagnosisApril 2, 2024 | ca.news.yahoo.comAlberta creating 2 mental health and addictions organizations, including Crown corporationApril 2, 2024 | msn.comThere’s Nothing Wrong With Having Hooded EyesApril 2, 2024 | msn.comA dietitian explains how a 'diet break' can make it easier to lose weight and keep it offSee More Headlines Receive NRXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today5/09/2024Next Earnings (Confirmed)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NRXP CUSIPN/A CIK1719406 Webwww.bigrockpartners.com Phone(484) 254-6134FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,150,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-202.53% Debt Debt-to-Equity RatioN/A Current Ratio0.36 Quick Ratio0.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.38) per share Price / Book-2.04Miscellaneous Outstanding Shares10,560,000Free Float8,332,000Market Cap$29.78 million OptionableOptionable Beta1.15 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Jonathan C. Javitt M.D. (Age 67)M.P.H., Co-Founder, Chief Scientist Officer & Chairman Comp: $873.7kMr. Stephen H. Willard Esq. (Age 63)Acting Corporate Secretary, CEO & Director Comp: $501.19kDr. Riccardo Panicucci Ph.D. (Age 62)Chief Technology Officer Comp: $240kDr. Seth L. Van Voorhees Ph.D. (Age 63)Treasurer Comp: $399.96kMr. Richard Clavano Narido (Age 46)Interim CFO, Principal Financial Officer & Principal Accounting Officer Suzanne MessereInvestor RelationsDr. Philip T. Lavin Ph.D. (Age 77)Chief Methodologist Dr. Dennis K. McBride Ph.D.Chief Strategy Officer & Senior ScientistMr. Matthew Patrick Duffy (Age 61)Chief Business Officer More ExecutivesKey CompetitorsTheratechnologiesNASDAQ:THTXEnlivex TherapeuticsNASDAQ:ENLVAcurx PharmaceuticalsNASDAQ:ACXPDaré BioscienceNASDAQ:DAREAprea TherapeuticsNASDAQ:APREView All CompetitorsInsiders & InstitutionsAdvisorShares Investments LLCBought 642,632 shares on 2/14/2024Ownership: 0.755%Aaron GorovitzBought 3,500 shares on 8/30/2023Total: $11,200.00 ($3.20/share)Jonathan C JavittBought 20,000 shares on 8/22/2023Total: $64,000.00 ($3.20/share)View All Insider TransactionsView All Institutional Transactions NRXP Stock Analysis - Frequently Asked Questions How have NRXP shares performed in 2024? NRx Pharmaceuticals' stock was trading at $46.00 on January 1st, 2024. Since then, NRXP stock has decreased by 93.9% and is now trading at $2.82. View the best growth stocks for 2024 here. Are investors shorting NRx Pharmaceuticals? NRx Pharmaceuticals saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 510,800 shares, an increase of 20.3% from the March 31st total of 424,500 shares. Based on an average daily volume of 205,600 shares, the short-interest ratio is presently 2.5 days. Approximately 6.7% of the shares of the stock are short sold. View NRx Pharmaceuticals' Short Interest. When is NRx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our NRXP earnings forecast. How can I listen to NRx Pharmaceuticals' earnings call? NRx Pharmaceuticals will be holding an earnings conference call on Tuesday, May 14th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were NRx Pharmaceuticals' earnings last quarter? NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) announced its quarterly earnings data on Friday, March, 29th. The company reported ($0.50) earnings per share (EPS) for the quarter. What ETF holds NRx Pharmaceuticals' stock? AdvisorShares Psychedelics ETF holds 105,043 shares of NRXP stock, representing 4.75% of its portfolio. When did NRx Pharmaceuticals' stock split? NRx Pharmaceuticals's stock reverse split before market open on Tuesday, April 2nd 2024. The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What guidance has NRx Pharmaceuticals issued on next quarter's earnings? NRx Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, March, 28th. The company provided EPS guidance of -0.400--0.400 for the period, compared to the consensus earnings per share estimate of -0.370. The company issued revenue guidance of -. How do I buy shares of NRx Pharmaceuticals? Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NRXP) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.